In a prospective study of patients with CD or UC receiving induction therapy with vedolizumab, low trough levels of vedolizumab at Week 6 (<19.0 μg/mL) are associated with need for additional doses (given at Week 10 and then every 4 weeks). All patients receiving these additional doses achieved a clinical response 4 weeks later.

Objectives:The total psoas area index (TPI) is an emerging alternative to the total skeletal muscle area index as a prognostic factor but has never been evaluated in metastatic pancreatic cancer (mPC).Methods: Areas were manually recorded, as previously described.Sex-specific cutoffs were identified by optimum stratification of TPI using log-rank χ 2 statistic associated with mortality to define sarcopenic psoas. Progression-free survival (PFS) and overall survival (OS) were the primary objectives. Two period groups were used as internal validation.Results: During the period study, 79 patients were treated for mPC. The TPI was correlated with PFS (hazards ratio, 0.81; P = 0.02) and OS (hazards ratio, 0.7; P < 0.001). Optimum thresholds defining sarcopenic psoas were less than 5.73 cm 2 /m 2 in men and less than 4.37 cm 2 /m 2 in women. Patients with sarcopenic psoas (62.0%) had shorter median PFS (2.9 months) compared with the others (6.6 months, adjusted P log-rank = 0.01), independently to the intensity of chemotherapy, weight loss, and performance status greater than 1. Similarly, OS was independently shorter in patients with sarcopenic psoas (7.6 months) versus the others (22.2 months, adjusted P < 0.001). These results were confirmed in the 2 period groups. Conclusions:A low TPI is a stronger independent prognostic factor in mPC.

Background: Pancreatic ductal adenocarcinoma (PDAC) is among the most common malignancies associated with venous thromboembolism (VTE). However, despite recommendations basing on Khorana score commonly known to predict the risk of VTE, thromboprophylaxis has not been prescribed routinely in clinical practice, especially in patients with advanced PDAC.Methods: Medical charts of patients consecutively treated for advanced PDAC from 2010 to 2019 without thromboprophylaxis were retrospectively reviewed. The cumulative incidence of VTE was estimated using Kaplan-Meier method. Factors associated with VTE were identified using a multivariate Cox's proportional hazard model with stepwise selection process. Similar analyses were performed for survivals. Early VTE was defined as VTE occurring within the third months from PDAC diagnosis.Results: A total of 155 patients were included (median age: 68 years; males: 56.1%; performance status 0-1: 85.8%) with metastatic (70.3%) or locally advanced disease (29.7%). At baseline, Khorana score was high (!3) for the vast majority of cases (94.3%). The cumulative incidences of VTE were 12.2% (95%